Erasca, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ERAS Nasdaq 2836 www.erasca.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Erasca, Inc.

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium - Sep 10th, 2026 6:00 am
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - Sep 8th, 2026 5:00 am
FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage - Sep 4th, 2026 12:40 pm
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma - Aug 24th, 2026 6:00 am
Erasca Reports Second Quarter 2026 Business Updates and Financial Results - Aug 11th, 2026 2:01 pm
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 10th, 2026 2:01 pm
Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns - Jul 15th, 2026 9:24 pm
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Jul 15th, 2026 2:01 pm
Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full? - Jul 15th, 2026 9:13 am
Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers - Jul 15th, 2026 8:10 am
Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results - Jul 14th, 2026 5:40 pm
Erasca Announces Pricing of Upsized Public Offering of Common Stock - Jul 13th, 2026 9:10 pm
Erasca Announces Proposed Public Offering of $500 Million of Common Stock - Jul 13th, 2026 2:19 pm
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors - Jul 13th, 2026 2:01 pm
Robinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ List - Jul 2nd, 2026 12:44 pm
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026? - Jul 2nd, 2026 8:46 am
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts - Jul 2nd, 2026 8:43 am
Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors - Jun 23rd, 2026 2:44 pm
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors - Jun 23rd, 2026 2:01 pm
Erasca (ERAS) Receives Encouraging Expert Feedback on ERAS-0015 Clinical Trials - Jun 11th, 2026 4:20 am